EGFR and hepatocellular carcinoma: In addition to directly interacting with the ABCB1 3′-UTR, miR-338-5p could target the EGFR/ERK1/2 pathway to inhibit the expression of ABCB1, resulting in increased sensitivity of hepatoma cells to DOX.